Posted by Michael Wonder on 18 Jul 2022
Azurity Pharmaceuticals announces FDA approval of Zonisade (zonisamide oral suspension)
18 July 2022 - The first and only FDA approved zonisamide oral liquid formulation.
Azurity Pharmaceuticals today announced the U.S. FDA approval of Zonisade (zonisamide) 100 mg/5 mL oral suspension as adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and older with epilepsy.
